Atea Pharmaceuticals, Inc. (AVIR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AVIR currently has 79.1M outstanding shares. with significant dilution risk as 70.5M authorized shares could dilute existing holders by 89.2%. The company has minimally diluted shareholders by 1.31% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 12, 2025 |
10-Q filing | 79.1M shares outstanding |
79M | 71M |
| Aug 07, 2025 |
10-Q filing | 83.7M shares outstanding |
84M | 71M |
| May 12, 2025 |
10-Q filing | 85.2M shares outstanding |
85M | 71M |
| Mar 06, 2025 |
10-K filing | 84.3M shares outstanding |
84M | 71M |
| Nov 07, 2024 |
S-3 filing: Atea Pharmaceuticals files an S-3 to offer and sell up to $500,000,000 in the aggregate of common stock, preferred stock and debt securities from time to time in one or more offerings. Common stock offered by us Shares of our common stock having an aggregate offering price of up to $200,000,000. |
84M | 71M |
| Nov 07, 2024 |
10-Q filing | 84.4M shares outstanding |
84M | 71M |
| Aug 07, 2024 |
10-Q filing | 84.3M shares outstanding |
84M | 11M |
| May 14, 2024 |
10-Q filing | 83.9M shares outstanding |
84M | 11M |
| Feb 28, 2024 |
10-K filing | 83.4M shares outstanding |
83M | 11M |
| Nov 08, 2023 |
10-Q filing | 83.4M shares outstanding |
83M | 11M |
| Aug 08, 2023 |
10-Q filing | 83.4M shares outstanding |
83M | 11M |
| May 08, 2023 |
10-Q filing | 83.3M shares outstanding |
83M | 11M |
| Feb 28, 2023 |
10-K filing | 83.2M shares outstanding |
83M | 11M |
| Nov 07, 2022 |
10-Q filing | 83.3M shares outstanding |
83M | 11M |
| Aug 08, 2022 |
10-Q filing | 83.3M shares outstanding |
83M | 11M |
| May 10, 2022 |
10-Q filing | 83.2M shares outstanding |
83M | 11M |
| Mar 01, 2022 |
POS AM filing: Atea Pharmaceuticals files a POS AM to offer common stock, preferred stock, and debt securities up to $500,000,000 in the aggregate. Includes an at-the-market offering of common stock through Jefferies LLC. |
83M | 11M |
| Feb 28, 2022 |
10-K filing | 82.8M shares outstanding |
83M | 11M |
| Nov 12, 2021 |
10-Q filing | 82.8M shares outstanding |
83M | 11M |
| Aug 12, 2021 |
10-Q filing | 82.7M shares outstanding |
83M | 11M |
| May 13, 2021 |
10-Q filing | 82.6M shares outstanding |
83M | 11M |
| Mar 30, 2021 |
10-K filing | 82.7M shares outstanding |
83M | 11M |
| Dec 10, 2020 |
10-Q filing | 82.6M shares outstanding |
83M | 11M |
| Oct 26, 2020 |
S-1/A filing: Atea Pharmaceuticals, Inc. is offering 11,000,000 shares of its common stock in its initial public offering, with an estimated initial public offering price between $22.00 and $24.00 per share. |
N/A | 11M |
| Oct 23, 2020 |
S-1/A filing: Atea Pharmaceuticals, Inc. is offering shares of its common stock in an initial public offering. |
N/A | 0 |
| Oct 09, 2020 |
S-1 filing: This S-1 filing outlines various scenarios for the issuance of common stock, options, and convertible securities, including those related to preferred stock conversion, dividends, employee compensation, debt financing, acquisitions, and strategic partnerships. |
N/A | 0 |